GSK released ' Nebilet(Nebivolol)' in the Korean market on 3 July.
Nebivolol is a β1 receptor blocker with nitric oxide-potentiating vasodilatory effect used in treatment of hypertension.
The Korean pharmaceutical industry is paying attention to Nebilet's future effect on the Korean market; there are alreadly several pharmaceutical companies producing antihypertensive drugs in Korea and their competition is likely to be keener.
Chong Kun Dang's 'Dilatrend(carvedilol)' has recorded last year 60.7 billion won of sales in prescription drug market(according to UBIST data) and its market share is 40% in the beta blocker market, followed by Hyundai Pharm's 'Tenormin'(16.0 billion won) and Merk‘s 'Concor Tab. 5mg'(9.0 billion won).
Especially, sales of Dilatrend have increased even after its generic came out in 2006.
It means the loyalty of doctors and patients to Dilatrend is higher than to any other antihypertensive drugs.<헬스코리아뉴스>
